Fund Immunotherapy In New Zealand

Prebrolizumab, keytruda is one of many immunotherapy treatments in New Zealand that are not funded by Pharmac and the New Zealand government. This is unacceptable. Many families are unable to pay for the treatment which can cost $7000 or more a month.

Our petition

"That the House of Representatives approve extra funding to Pharmac so that the drug pembrolizumab can be made available to all New Zealanders with advanced melanoma, regardless of socio-economic status."